
Anti-Inflammatory Therapeutics Market Report 2026
Global Outlook – By Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Anti-Inflammatory Biologics), By Indication (Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases, Other Inflammatory Diseases), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies) – Market Size, Trends, Strategies, and Forecast to 2035
Anti-Inflammatory Therapeutics Market Overview
• Anti-Inflammatory Therapeutics market size has reached to $117.28 billion in 2025 • Expected to grow to $152.04 billion in 2030 at a compound annual growth rate (CAGR) of 5.6% • Growth Driver: Rising Incidence Of Inflammatory Bowel Disease Fuels Growth In The Anti-Inflammatory Therapeutics Market • Market Trend: Innovative Drugs Strengthen Market Position Of Key Players In The Anti-Inflammatory Therapeutics Sector • North America was the largest region in 2025 and Europe is the fastest growing region.What Is Covered Under Anti-Inflammatory Therapeutics Market?
Anti-inflammatory therapeutics refer to prescription medications that treat pain, lessen inflammation, and lower a high body temperature. It acts as a host response modifier and plays a crucial role in managing acute and chronic headaches, painful phases, sprains, and strain problems. The main types of drug classes for anti-inflammatory therapeutics are nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and anti-inflammatory biologics. Nonsteroidal anti-inflammatory drugs refer to non-opioid analgesic drugs that are typically used by people to relieve mild bodily pain symptoms. The various indications include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel diseases, and others, and are distributed through various distribution channels such as retail pharmacies, hospital pharmacies, and online distribution.
What Is The Anti-Inflammatory Therapeutics Market Size and Share 2026?
The anti-inflammatory therapeutics market size has grown steadily in recent years. It will grow from $117.28 billion in 2025 to $122.27 billion in 2026 at a compound annual growth rate (CAGR) of 4.3%. The growth in the historic period can be attributed to rising prevalence of arthritis, increasing cases of inflammatory bowel diseases, growth in hospital pharmacy networks, adoption of corticosteroids, demand for pain management drugs.What Is The Anti-Inflammatory Therapeutics Market Growth Forecast?
The anti-inflammatory therapeutics market size is expected to see strong growth in the next few years. It will grow to $152.04 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to development of targeted biologics, integration of AI in drug discovery, expansion of online pharmacies, increasing geriatric population, rising focus on personalized medicine. Major trends in the forecast period include personalized anti-inflammatory therapies, increased use of biologic drugs, minimally invasive drug delivery systems, growth in chronic pain management, expansion of online pharmacy distribution.Global Anti-Inflammatory Therapeutics Market Segmentation
1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Anti-Inflammatory Biologics 2) By Indication: Arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory Bowel Diseases, Other Inflammatory Diseases 3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies Subsegments: 1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Aspirin, Naproxen, Diclofenac, Celecoxib, Indomethacin, Ketoprofen 2) By Corticosteroids: Prednisone, Dexamethasone, Hydrocortisone, Methylprednisolone, Triamcinolone, Betamethasone 3) By Anti-Inflammatory Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Monoclonal Antibodies, Recombinant Proteins, Fusion ProteinsWhat Is The Driver Of The Anti-Inflammatory Therapeutics Market?
The increasing prevalence of inflammatory bowel disease is expected to propel the growth of the anti-inflammatory therapeutics market going forward. Inflammatory bowel disease (IBD) is a chronic illness resulting in inflammation of the gastrointestinal tract. Anti-inflammatory therapeutics play a crucial role in treating Crohn's disease by reducing inflammation, managing the symptoms of the disease, and reducing the risk of surgery. For instance, in June 2023, according to Crohn's and Colitis Canada, a Canada-based non-profit organization, there will be 470,000 inflammatory bowel disease (IBD) sufferers in Canada by 2035, up from an estimated 322,600 in 2023. Therefore, the increasing prevalence of inflammatory bowel disease is driving the growth of the anti-inflammatory therapeutics industry.Key Players In The Global Anti-Inflammatory Therapeutics Market
Major companies operating in the anti-inflammatory therapeutics market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Co. Ltd., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Cipla Inc., Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd.Global Anti-Inflammatory Therapeutics Market Trends and Insights
Major companies operating in the anti-inflammatory therapeutics market are focusing on developing innovative biologic therapies to improve treatment outcomes for patients with chronic inflammatory conditions. These advanced therapies are designed to offer targeted immune modulation, enhanced efficacy, and better tolerability compared to conventional treatments such as corticosteroids. For instance, in February 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, and Sanofi, a France-based pharmaceutical and healthcare company, launched Kevzara (sarilumab), the first and only anti-inflammatory biologic recommended for adult patients with polymyalgia rheumatica (PMR) who do not respond adequately to corticosteroids or are unable to tolerate corticosteroid tapering. This novel IL-6 receptor inhibitor provides a more effective and steroid-sparing therapeutic option, addressing a significant unmet need in PMR management and strengthening the companies' positions in the anti-inflammatory therapeutics market.What Are Latest Mergers And Acquisitions In The Anti-Inflammatory Therapeutics Market?
In June 2023, Merck & Co., Inc., a US-based biopharmaceutical company, completed the acquisition of Prometheus Biosciences, Inc. for an undisclosed amount. Through this acquisition, Merck aims to strengthen its immunology portfolio by integrating Prometheus’ precision medicine capabilities and its lead candidate PRA023, a targeted therapy being developed for immune-mediated diseases such as ulcerative colitis and Crohn’s disease. Prometheus Biosciences, Inc. is a US-based biotechnology company focused on developing anti-inflammatory therapeutics.Regional Insights
North America was the largest region in the anti-inflammatory therapeutics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.What Defines the Anti-Inflammatory Therapeutics Market?
The anti-inflammatory therapeutics market consists of sales of Ibuprofen, naproxen, and diclofenac. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.How is Market Value Defined and Measured?
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.What Key Data and Analysis Are Included in the Anti-Inflammatory Therapeutics Market Report 2026?
The anti-inflammatory therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anti-inflammatory therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.Anti-Inflammatory Therapeutics Market Report Forecast Analysis
| Report Attribute | Details |
|---|---|
| Market Size Value In 2026 | $122.27 billion |
| Revenue Forecast In 2035 | $152.04 billion |
| Growth Rate | CAGR of 4.3% from 2026 to 2035 |
| Base Year For Estimation | 2025 |
| Actual Estimates/Historical Data | 2020-2025 |
| Forecast Period | 2026 - 2030 - 2035 |
| Market Representation | Revenue in USD Billion and CAGR from 2026 to 2035 |
| Segments Covered | Drug Class, Indication, Distribution Channel |
| Regional Scope | Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa |
| Country Scope | The countries covered in the report are Australia, Brazil, China, France, Germany, India, ... |
| Key Companies Profiled | Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Co. Ltd., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Cipla Inc., Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd. |
| Customization Scope | Request for Customization |
| Pricing And Purchase Options | Explore Purchase Options |
